Dr. Reddy’s Laboratories to Participate in CLSA Investor Conference

Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.

On June 11, 2025, Dr. Reddy’s Laboratories announced its participation in an investor conference organized by CLSA, scheduled for June 18, 2025, in Hyderabad. This meeting, intended for institutional investors, underscores the company’s ongoing efforts to engage with stakeholders and provide insights into its operations and strategic direction.

The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories is a prominent pharmaceutical company based in Hyderabad, India. It specializes in the development and production of a wide range of pharmaceutical products, focusing on generic medications and active pharmaceutical ingredients. The company is listed on major stock exchanges including the National Stock Exchange of India, BSE Limited, and the New York Stock Exchange.

Average Trading Volume: 2,121,312

Technical Sentiment Signal: Strong Buy

Current Market Cap: $13.16B

Learn more about RDY stock on TipRanks’ Stock Analysis page.